Skip to main content

Table 1 Baseline characteristics

From: Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer

  CTRCD (n = 13) No CTRCD (n = 59) p value
Age (years) 47.2 ± 7.7 49.2 ± 8.8 0.471
Hypertension (%) 2 (15.4) 10 (16.9) 1.000
ACEi or ARB use (%) 1 (7.7) 6 (10.2) 0.629
Beta-blocker use (%) 0 (0.0) 3 (5.1) 0.545
Diabetes mellitus (%) 1 (7.7) 4 (6.8) 1.000
Dyslipidemia (%) 2 (15.4) 5 (8.5) 0.602
Smoking (%) 1 (7.7) 2 (3.4) 0.455
BMI (kg/m2) 24.9 ± 4.5 23.8 ± 3.9 0.412
Epirubicin (%) 5 (38.5) 29 (49.2) 0.485
Epirubicin dose (mg/m2) 336.0 ± 68.4 314.5 ± 88.4 0.610
Doxorubicin (%) 5 (38.5) 16 (27.1) 0.504
Doxorubicin dose (mg/m2) 304.8 ± 38.3 266.6 ± 32.0 0.038
Cyclophosphamide (%) 8 (61.5) 38 (64.4) 1.000
Cyclophosphamide dose (mg/m2) 2550.0 ± 424.3 2460.0 ± 222.8 0.388
Docetaxel (%) 4 (30.8) 19 (32.2) 1.000
Docetaxel dose (mg/m2) 337.5 ± 75.0 331.6 ± 150.7 0.940
Radiation therapy (%) 7 (53.8) 27 (45.8) 0.597
Radiation dose (cGy) 5754.9 ± 398.8 5628.4 ± 362.3 0.426
  1. CTRCD: cancer therapeutics-related cardiac dysfunction, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index